Skip to main content
SpringerLink
Log in
Book cover

Small Molecules in Oncology pp 189–197Cite as

Temsirolimus

  • Chapter
  • First Online:

Part of the book series: Recent Results in Cancer Research ((RECENTCANCER,volume 184))

Abstract

Temsirolimus, an ester of sirolimus (rapamycin), selectively inhibits the kinase mammalian target of rapamycin and consequently blocks the translation of cell cycle regulatory proteins and prevents overexpression of angiogenic growth factors.

Patients with advanced renal cell carcinoma (RCC) and a poor prognosis who received a once-weekly intravenous (IV) infusion of temsirolimus 25 mg, experienced significant survival benefits when compared with patients receiving standard interferon-α (IFNα) therapy in a large phase III clinical study. In this study, median overall survival was 10.9 vs. 7.3 months and objective response rates were 8.6% in temsirolimus recipients vs. 4.8% IFNα recipient group.

Temsirolimus monotherapy recipients experienced significantly fewer grade 3 or 4 adverse events and had fewer withdrawals for adverse events than patients receiving IFNα.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   199.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   259.00
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  • Linehan WM, Zbar B, Bates SE et al (2001) Cancer of the kidney and ureter. In: DeVita VT, Hellman S, Rosenberg SA (eds) Cancer: principles and practice of oncology. Lippincott, Williams and Wilkins, Philadelphia, PA, pp 1362–1396

    Google Scholar 

  • Jemal A, Siegel R, Ward E et al (2007) Cancer Statistiscs, 2007. CA Cancer J Clin 57:43–66

    Article  PubMed  Google Scholar 

  • Larkin JMG, Chowdhury S, Gore ME (2007) Drug insight: advances in renal cell carcinoma and the role of target therapies. Nat Clin Pract Oncol 4(8):470–479

    Article  CAS  PubMed  Google Scholar 

  • Alexandrescu DT, Dasanu CA (2006) Kidney cancer therapy: new perspectivies and avenues. Expert Opin Pharmacother 7(18):2481–2493

    Article  CAS  PubMed  Google Scholar 

  • Motzer RJ, Bukowsky RM (2006) Targeted therapy for metastatic renal carcinoma. J Clin Oncol 24(35):5601–5608

    Article  CAS  PubMed  Google Scholar 

  • Aass N, De Mulder HM, Mickisch GHJ et al (2005) Randomized phase II/III trial of interferon alfa-2a with and without 13- cis –retinoic acid in patients with progressive metastatic renal cell carcinoma: the European organization for research and treatment of cancer genito-urinary tract cancer group (EOTORC 30951). J Clin Oncol 23:4172–4178

    Article  CAS  PubMed  Google Scholar 

  • Rosemberg SA, Lotze MT, Muul ML et al (1985) Observations on the systemic administration of autologus lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer. N Engl J Med 313(23):1485–1492

    Article  Google Scholar 

  • Escudier B (2007) Advanced renal cell carcinoma: current and emerging management strategies. Drugs 67(9):1257–1264

    Article  CAS  PubMed  Google Scholar 

  • Hudes G, Carducci M, Tomczak P et al (2007) Temsirolimus, interferon alfa, or both for advanced renal cell carcinoma. N Engl J Med 356:2271–2281

    Article  CAS  PubMed  Google Scholar 

  • Peralba JM, DeGraffenried L, Friedrichs W et al (2003) Pharmacodynamic evaluation of CCI-779, an inhibitor of mTOR, in cancer patients. Clin Cancer Res 9:2887–2892

    CAS  PubMed  Google Scholar 

  • Guertin DA, Sabatini DM (2005) An expanding role for mTOR in cancer. Trends Mol Med 11: 353–361

    Article  CAS  PubMed  Google Scholar 

  • Martin DE, Hall MN (2005) The expandind TOR signaling network. Curr Opin Cell Biol 17: 158–166

    Article  CAS  PubMed  Google Scholar 

  • Thomas GV, Tran C, Mellinghoff IK et al (2006) Hypoxia inducible factors determines sensitivity to ihibitors of mTOR in kidney cancer. Nad Med 12:122–127

    Article  CAS  Google Scholar 

  • Sabers CJ, Matrin MM, Brunn JJ et al (1995) Isolation of a protein target of FKBP 12-rapamycin complex in mammalian cells. J Biol Chem 270(2):815–822

    Article  CAS  PubMed  Google Scholar 

  • Neshat MS, Mellinghoff IK, Tran C et al (2001) Enhancedsensitivity of PTEN-deficient tumors to inhibition of FRAP/mTOR. Proc Natl Acad Sci U S A 98(18):10314–10319

    Article  CAS  PubMed  Google Scholar 

  • Podsypanina K, Lee RT, Politis C et al (2001) An inhibitor of mTOR reduces neoplasia and normalizes p70/S6 kinaseactivity in Pten+/- mice. Proc Natl Acad Sci US A 98:10320–10323

    Article  CAS  Google Scholar 

  • Yu K, Toral-Barza L, Discafani C et al (2001) mTOR, a novel target in breast cancer : the effect of CCI-779, an mTOR inhibitor, in preclinical models of breast cancer. Endocr Relat Cancer 8(3):249–258

    Article  PubMed  Google Scholar 

  • HidalgoM BucknerJC, Erlichman C et al (2006) A phase Iand pharmacokinetic study of temsirolimus (CCI-779)administered intravenously daily for 5 days every 2 weeks to patients with advanced cancer. Clin Cancer Res 12:5755–5763

    Article  Google Scholar 

  • Raymond E, Alexandre J, Faivre S et al (2004) Safety and pharmacokinetics of escalated doses of weekly intravenous infusion of CCI-779, a novel mTOR inhibitor, in patients with cancer. J Clin Oncol 22:2336–2347

    Article  CAS  PubMed  Google Scholar 

  • Atkins MB, Hidalgo M, Stadler WM et al (2004) Randomized phase II study of multiple dose levels of CCI-779, a novel mammalian target of rapamycin kinase inhibitor, in patients with advanced refractory renal cell carcinoma. J Clin Oncol 22:909–918

    Article  CAS  PubMed  Google Scholar 

  • Yang JC, Haworth L, Sherry RM et al (2003) A randomized trial of bevacizumab, an antivascular endothelia growth factor antibody, for metastatic renal cancer. N Engl J Med 349:427–434

    Article  CAS  PubMed  Google Scholar 

  • Oza AM et al (2005) A phase II study on temsirolimus (CCI-779) in patients with metastaic and/or recurrent endometrial cancer. Proc. 17th Symp Mol. Targets Cancer Thera. Philadelphia, USA, November, 197 AB269

    Google Scholar 

  • Galanis E et al (2005) Phase II trial of tensirolimus (CCI- 779) in recurrent glioblastoma multiforme: a north central cancer treatment group study. J Clin Oncol 23:5294–5304

    Article  CAS  PubMed  Google Scholar 

  • Chang SM et al (2005) Phase II study of CCI-779 in patients with recurrent glioblastoma multiforme. Invest New Drugs 23:357–361

    Article  CAS  PubMed  Google Scholar 

  • Witzig TE et al (2005a) Phase II trial of single-agent tensirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 23:5347–5356

    Article  CAS  PubMed  Google Scholar 

  • Witzig TE et al (2005b) Phase II trial of single-agent tensirolimus (CCI-779) for relapsed mantle cell lymphoma. J Clin Oncol 23:5347–5356

    Article  CAS  PubMed  Google Scholar 

  • Ansell SM et al (2008) Low-dose, single-agent temsirolimus for relapsed mantle cell lymphoma. A phase 2 trial in the north central cancer treatment group. Cancer 113(3):508–514

    Article  CAS  PubMed  Google Scholar 

  • Verhoef G, Hess G et al (2008) Phase III study of patients with relapsed, refractory mantle cel lymphoma treated with temsirolimus compared with investigator’s choice therapy. 13th Congress of the European Hematology Association (EHA)

    Google Scholar 

  • Hess G, Verhoef G et al (2008) Phase III study of patients with relapsed , refractory mantle cel lymphoma treated with temsirolimus compared with investigator’s choice therapy. 44th Annual Meeting of the American Society of Clinical Oncology (ASCO)

    Google Scholar 

  • Motzer RJ, Figlin RA, Hutson TE, et al (2008) Overall survival with sunitinib versus interferon (IFN)-alfa as first-line treatment of metastatic renal cell carcinoma (mRCC). 44th Annual Meeting of the American Society of Clinical Oncology (ASCO)

    Google Scholar 

  • Escudier B, Pluzanska A, Koralewski P, Ravaud A, Bracarda S, Szczylik C, Chevreau C, Filipek M, Melichar B, Bajetta E, Gorbunova V, Bay JO, Bodrogi I, Jagiello-Gruszfeld A, Moore N (2007) AVOREN trial investigators. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial. Lancet 370(9605):2103–2111

    Article  PubMed  Google Scholar 

  • Rini BI, Halabi S, Rosenberg JE, Stadler WM, Vaena DA, Ou SS, Archer L, Atkins JN, Picus J, Czaykowski P, Dutcher J, Small EJ (2008) Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206. J Clin Oncol 26:5422–5428

    Article  CAS  PubMed  Google Scholar 

  • Szczylik C, Demkow T, Staehler M, Rolland F, Negrier S, Hutson TE, Bukowski RM, Scheuring UJ, Burk K and Escudier B (2007) Randomized phase II trial of first-line treatment with sorafenib versus interferon in patients with advanced renal cell carcinoma: final results. J Clin Oncol 25(Suppl):abstr. 5025

    Google Scholar 

  • Duran I, Kortmansky J, Singh D, Hirte H, Kocha W, Goss G, Le L, Oza A, Nicklee T, Ho J, Birle D, Pond GR, Arboine D, Dancey J, Aviel-Ronen S, Tsao MS, Hedley D, Siu LL (2006) A phase II clinical and pharmacodynamic study of temsirolimus in advanced neuroendocrine carcinomas. Br J Cancer 95(9):1148–1154

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Urology, SLK-Kliniken Heilbronn GmbH, Medizinsche Klinik III, Am Gesundbrunnen 20–26, 74078, Heilbronn, Germany

    Jens J. Rassweiler

Authors
  1. Christian Stock
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Massimo Zaccagnini
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Michael Schulze
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Dogu Teber
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Jens J. Rassweiler
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Jens J. Rassweiler .

Editor information

Editors and Affiliations

  1. Medizinische Klinik III, SLK-Kliniken Heilbronn GmbH, Am Gesundbrunen 20-26, Heilbronn, 74078, Germany

    Uwe M. Martens

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Stock, C., Zaccagnini, M., Schulze, M., Teber, D., Rassweiler, J.J. (2010). Temsirolimus. In: Martens, U. (eds) Small Molecules in Oncology. Recent Results in Cancer Research, vol 184. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-01222-8_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-642-01222-8_13

  • Published:

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-642-01221-1

  • Online ISBN: 978-3-642-01222-8

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation